Data+ Awards: BI helps Quintiles speed new drugs to market

Developing a new drug can cost millions of dollars and require years of research. The quicker a pharmaceutical company gets a product to market, the less time and money it spends on R&D and the faster it can begin to earn a return on its investment.

Technologies that can speed up a drug's trial period and more quickly analyze its odds of success can have a huge impact on the bottom line.

Quintiles knows that firsthand. The $4.8 billion company provides clinical research services to the pharmaceutical industry. Among other things, Quintiles plans and monitors clinical trials, recruits patients for trials and submits materials to regulatory agencies.

For the past four years the Cambridge, Mass.-based company has worked to create an integrated suite of software modules to handle all phases of drug research, development and trials.

Its software platform, Infosario, integrates the data and processes associated with a drug's life cycle and includes a data engine to collect, clean and prepare data for analysis. The data can be combined with clinical research data and information from other sources to provide predictive analysis.

Formally launched in 2010, Infosario uses elements from Oracle Business Intelligence Enterprise Edition, Siebel's CRM system, SAS Analytics, Microsoft SQL Server and Informatica's Master Data Management system, as well as Tibco's Spotfire data discovery and visualization tool. At its core is the Quintiles Data Factory, which contains the data operations and collection tools for extracting and organizing clinical and operational data from other repositories.

An executive at a Quintiles customer, a major pharmaceutical company, notes that the traditional method of planning a drug trial involves examining data from prior trials to develop the best approach. Infosario allows the company to design drug trials more quickly and effectively.

ROI

The Quintiles Infosario system allows researchers to revisit decisions made earlier within the same drug trial. That's a big benefit, says Quintiles CIO Richard Thomas, because "clinical trials take six, seven years, so feedback loops collect a lot of data along the way."

2015 State of The IT Channel Survey : IT'S TIME!!! Fill in this year's State of the IT Channel Survey and be in the running to win great prizes. CLICK HERE

Join the ARN newsletter!

Error: Please check your email address.

Tags applicationssoftwareQuintilesbusiness intelligence

More about InformaticaMicrosoftOracleSASTibco

ARN Directory | Distributors relevant to this article

ARN Directory | Vendors relevant to this article

Show Comments
 

Latest News

02:41PM
PernixData sets its sights on A/NZ
01:13PM
Exclusive: Huawei sponsors AFL's Gold Coast Suns
12:40PM
Cloud drives 40 per cent channel growth for Kaseya
12:36PM
Hyland names Bob Dunn as first country manager for Australia
More News
14 Apr
Dell Solutions Tour Melbourne
15 Apr
LIVE WEBCAST Websense 2015 Threat Report: 8 High-Risk Lessons
21 Apr
APJ Progress Spark Conference
22 Apr
2015 Innotribe Startup Challenge
View all events